Absci stock price the "Absci stock price" was up 2

The "Absci stock price" was up 2.1% intraday, outperforming biotech peers. Analysts attribute gains to strategic collaborations announced with AI drug developers, an increasingly hot segment in healthcare innovation. This company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +13.6%. Several equities analysts recently commented on ABSI shares. Morgan Stanley dropped their price objective on shares of Absci from $6.40 to $5.89 and set an "overweight" rating for the company in a research note on Monday, August 18th. JPMorgan Chase & Co. assumed coverage on Absci in a research report on Thursday. They issued an "overweight" rating for the company. Wall Street Zen cut Absci from a "hold" rating to a "strong sell" rating in a report on Saturday, August 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Absci in a report on Saturday, September 27th. Finally, Needham & Company LLC dropped their price target on shares of Absci from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Absci presently has an average rating of "Moderate Buy" and a consensus price target of $7.98. Macroeconomic softness has not deterred gains in "Absci stock price", highlighting investor focus on high-growth biotech sectors. This contrasts with lagging pharma-heavy indices.